OncoPharm Rituximab
8 snips
Aug 9, 2018 Dive into the fascinating journey of rituximab from its dosage origins to its pivotal role in treating B-cell malignancies. The discussion highlights key insights from early clinical trials that shaped current practices. Listeners will also geek out over the latest data on the number needed to treat (NNT) in diffuse large B-cell lymphoma (DLBC). Plus, learn about rituximab's mechanisms, potential side effects, and essential infusion management tips.
AI Snips
Chapters
Transcript
Episode notes
Rituximab Dose Legend
- Rituximab's dose was supposedly decided by how much drug was left, not by dose-finding studies.
- John Bazar initially couldn't find literature to support this until he dug deeper.
Rituximab Early Phase One Dosing
- Early rituximab phase one trials showed no dose-limiting toxicity up to 500 mg/m2.
- Many enrolled patients were effectively underdosed by today's standards.
Pragmatic Dose Determination
- The 375 mg/m2 rituximab dose came from limited drug supply for planned phase two trials.
- This pragmatic choice rather than scientific optimization defined current dosing.